1. Home
  2. JYNT vs AARD Comparison

JYNT vs AARD Comparison

Compare JYNT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$7.83

Market Cap

117.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

HOLD

Current Price

$5.07

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
AARD
Founded
2010
2017
Country
United States
United States
Employees
N/A
28
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.7M
107.7M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
JYNT
AARD
Price
$7.83
$5.07
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$17.00
$15.29
AVG Volume (30 Days)
61.5K
117.4K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
133.93
43.11
EPS
0.14
N/A
Revenue
$117,696,356.00
N/A
Revenue This Year
$12.23
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$57.79
N/A
Revenue Growth
15.49
N/A
52 Week Low
$7.50
$3.35
52 Week High
$10.67
$17.94

Technical Indicators

Market Signals
Indicator
JYNT
AARD
Relative Strength Index (RSI) 37.49 35.99
Support Level $8.04 $3.38
Resistance Level $9.43 $6.01
Average True Range (ATR) 0.18 0.69
MACD -0.02 -0.21
Stochastic Oscillator 10.77 8.66

Price Performance

Historical Comparison
JYNT
AARD

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: